Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Trefoil Factor 3 in human serum as a predictor of disease activity in Egyptian ulcerative colitis patients and its role in colorectal cancer
Publication Year: 2024 Source: Egypt J Immunol PMID: 39404647
No Abstract
Functional and postoperative outcomes in ideal pouch-anal anastomosis in patients with parkinson disease and multiple sclerosis
Publication Year: 2024 Source: Langenbecks Arch Surg PMID: 39404852
No Abstract
Open vs. laparoscopic vs. robotic pouch excision: unveiling the best approach for optimal outcomes
Publication Year: 2024 Source: Tech Coloproctol PMID: 39404860
No Abstract
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in pediatric Inflammatory Bowel Disease: clinical characteristics and outcomes
Publication Year: 2024 Source: Eur J Pediatr PMID: 39404873 DOI: 10.1007/s00431-024-05772-4
Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) in children with inflammatory bowel disease (IBD) has been reported only anecdotally. This study aimed at describing the clinical features and outcomes of children diagnosed with both IBD and HLH/MAS. Data on IBD and HLH/MAS characteristics, biochemical, microbiological and genetic assessments, treatments, and outcomes …
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis
Publication Year: 2024 Source: Adv Ther PMID: 39404996
No Abstract
Outer membrane barrier impairment by envC deletion reduces gut colonization of Crohn's disease pathobiont Escherichia coli
Publication Year: 2024 Source: Microbiology (Reading) PMID: 39405098
No Abstract
From probiotic chassis to modification strategies, control and improvement of genetically engineered probiotics for inflammatory bowel disease
Publication Year: 2024 Source: Microbiol Res PMID: 39405668 DOI: 10.1016/j.micres.2024.127928
With the rising morbidity of inflammatory bowel disease (IBD) year by year, conventional therapeutic drugs with systemic side effects are no longer able to meet the requirements of patients. Probiotics can improve gut microbiota, enhance intestinal barrier function, and regulate mucosal immunity, making them a potential complementary or alternative therapy …
Oleanolic acid 28-O-β-D-glucopyranoside: A novel therapeutic agent against ulcerative colitis via anti-inflammatory, barrier-preservation, and gut microbiota-modulation
Publication Year: 2024 Source: Biomed Pharmacother PMID: 39405905
No Abstract
Farnesol ameliorates DSS-induced IBD by regulating inflammatory cytokines, repairing the intestinal barrier, reversing the gut microbiota imbalance, and influencing fecal metabolome in C57BL/6 mice
Publication Year: 2024 Source: Biomed Pharmacother PMID: 39405907 DOI: 10.1016/j.biopha.2024.117518
The incidence of inflammatory bowel disease (IBD) is rising globally, increasing interest in food ingredients for its prevention and control. This study evaluated the effect of farnesol (FAR), a key component of pomelo flower volatile oil, on dextran sodium sulfate (DSS)-induced colitis in C57BL/6 mice. FAR significantly alleviated DSS-induced colitis …
Involvement of autophagy and gut dysbiosis in ambient particulate matter-induced colonic inflammation
Publication Year: 2024 Source: Ecotoxicol Environ Saf PMID: 39405963
No Abstract
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide